Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Contrarius Global Equity Fund Waystone Management Company (IE) Limited | “Intellia is leading the way with two phase three CRISPR-Cas9 in-vivo clinical trials—one for ATTR-CM and another for hereditary angioedema—delivered via a single intravenous infusion without chemotherapy. The one-and-done approach is highly scalable, lowers adherence risk, and could command high margins even at modest market share. ATTR alone is a rapidly growing multi-billion-dollar market, and Intellia's current market cap is around $2 billion, leaving significant upside if approvals materialize. BSD Analysis: Intellia's in-vivo delivery and single-dose regimen create a differentiated profile versus chronic RNAi or antibody therapies. If phase 3 data are positive, pricing power and gross margins should be substantial, supporting a step-function in FCF. Risks center on clinical readouts and competitive responses, but risk-reward is attractive given small cap and large TAM.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
